MiNK Therapeutics Reports Clinical Progress with iNKT Cell Therapy, Targets Phase II Gastric Cancer Data by End of 2025
核心洞察
MiNK Therapeutics achieved a complete clinical response in a 49-year-old man with metastatic testicular cancer using invariant natural killer T cell therapy, with durable remission published in Nature's Oncogene.
The company reported greater than 40% tumor shrinkage in a refractory gastric cancer patient, prompting an ongoing Phase II trial at Memorial Sloan Kettering Cancer Center with top-line data expected by end of 2025.
MiNK reduced Q2 operating cash burn by over 30% year-over-year and raised an additional $13 million through equity sales, extending cash runway through mid-2026.
MiNK Therapeutics has demonstrated significant clinical progress with its invariant natural killer T cell (iNKT) therapy platform, reporting a complete clinical response in metastatic testicular cancer and substantial tumor reduction in gastric cancer patients. The company expects to deliver Phase II gastric cancer data by the end of 2025 while advancing multiple programs through strategic partnerships and improved operational efficiency.
Clinical Breakthrough in Testicular Cancer
The company achieved a notable clinical milestone with a complete response in a 49-year-old man with metastatic testicular cancer. This patient's durable remission was recently published in Nature's Oncogene, providing peer-reviewed validation of MiNK's iNKT therapy efficacy. The case represents a significant advancement in the application of off-the-shelf invariant natural killer T cells for solid tumor treatment.
Gastric Cancer Program Shows Promise
MiNK reported greater than 40% tumor shrinkage in a refractory gastric cancer patient, results that prompted the initiation of an ongoing Phase II trial at Memorial Sloan Kettering Cancer Center. The company expects to report top-line data from this Phase II gastric cancer trial by the end of 2025, representing a key catalyst for the program's advancement.
Financial Position and Operational Efficiency
The company demonstrated improved operational discipline by reducing Q2 operating cash burn by over 30% year-over-year. MiNK reported a net loss of $4.2 million or $1.06 per share for Q2 2025, compared to $2.7 million or $0.73 per share for the same period in 2024. For the first six months of 2025, net loss was $7 million or $1.76 per share, compared to $6.5 million or $1.82 per share for the corresponding period in 2024.
The company's cash balance at the end of Q2 was $1.7 million, but MiNK has since strengthened its financial position by raising an additional $13 million through equity sales. This funding extends the company's cash runway through the middle of 2026, achieved through deliberate burn rate reduction, streamlined operations, and strategic integration of high-impact funding.
Pipeline Advancement and Strategic Partnerships
CEO Jennifer S. Buell emphasized that MiNK continues to be "the most clinically advanced company, industrializing off-the-shelf, invariant natural killer T cells." The company has outlined multiple late-stage catalysts beyond the gastric cancer data, including the initiation of a GvHD Phase I trial and further advancement of the MiNK-215 engineered iNKT program.
MiNK anticipates that its GvHD and ARDS programs will advance with minimal capital impact due to Department of Defense (DoD) funding through an STTR grant and supportive funding from University of Wisconsin Cancer Center (搜索) grants. This external funding support allows the company to pursue multiple programs in parallel while preserving shareholder value.
The company continues to expand its partnerships as part of its strategy to advance the iNKT cell therapy platform across multiple indications, positioning itself at the forefront of off-the-shelf cellular immunotherapy development.